MedTrace Logo

A Trial to Study BAY1753011 in Patients With Congestive Heart Failure

NCT03901729 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 482

Last updated 2022-04-18

No results posted yet for this study

Summary

To assess the efficacy of 30 mg of BAY1753011, with or without furosemide, versus furosemide alone in patients with heart failure and objective evidence of congestion.

Conditions

  • Heart Failure (HF)

Interventions

DRUG

BAY 1753011

Tablet; 30mg or 5mg unit; 30mg once daily in the morning; Oral

OTHER

Placebo BAY 1753011

Tablet; Once daily in the morning; Oral

DRUG

Furosemide

Tablet; 40mg unit; 80mg once daily in the morning; Oral

OTHER

Placebo Furosemide

Tablet; Once daily in the morning; Oral

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-29
Primary Completion
2021-04-16
Completion
2021-05-21

Countries

  • Austria
  • Bulgaria
  • Greece
  • Hungary
  • Israel
  • Italy
  • Poland
  • Portugal
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03901729 on ClinicalTrials.gov